Purchase this article with an account.
So Young Han, Sang Woong Moon, Jaeryung Oh, Hee Yoon Cho, Hyeong Gon Yu, Su Jeong Song; Incidence And Risk Factors Of Submacular Hemorrhage After Intravitreal Ranibizumab Injection For Neovascular Age Related Macular Degeneration: The Results From KORIA Study Group. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3809.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To analyze the incidence and risk factors for development or increase of macular hemorrhage after intravitreal ranibizumab injection for neovascular AMD.
Retrospective chart review of 220 patients (220 eyes) from 5 hospitals who received intravitreal ranibizumab injection for neovascular AMD from 1 June 2009 to 30 June 2010. Systemic conditions (age, gender, presence of diabetes, hypertension, cardiovascular disease, smoking, use of anticoagulation agent) and total injection number, presence of hemorrhage at initial exam, angiographic type of choroidal neovascular membrane (CNV) were evaluated.
The incidence of development or increase of macular hemorrhage including vitreous hemorrhage was 8% (18/220). And risk factor of macular hemorrhage was presence of diabetes. (OR: 2.16, CI: 1.07-8.13). When patients had both diabetes and hypertension, the risk of macular hemorrhage after injection was increased to 4.8 folds. (OR:4.84, CI: 1.24-18.85)
The systemic condition of patients was important risk factor of development or increase of macular hemorrhage after intravitreal ranibizumab injection for neovascular AMD. More consideration on status of diabetes and hypertension of patients who receives ranibizumab for neovascular AMD should be made.
This PDF is available to Subscribers Only